Commentary|Videos|June 3, 2025
ASCO 2025: Top Data Highlights from 6/3
Author(s)Yan Leyfman, MD, Chandler Park, MD, MSc, FACP
Fact checked by: Kristi Rosa
MedNews Week host Yan Leyfman, MD, speaks with 2 key opinion leaders at ASCO 2025 about the top data highlights of the day.
Advertisement
On the Clock is a dynamic video series from MedNews Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. In each episode, key opinion leaders share the data they’re most excited about—highlighting the studies, trends, and breakthroughs that could shape clinical practice.
In this episode, host Yan Leyfman, MD, spoke with the following key opinion leaders:
- MinhTri Nguyen, MD, of Stanford Cancer Center
- Arturo Loaiza-Bonilla, MD, FACP, MEd, of St. Luke's University Health Network
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/12
5